Generic Name and Formulations:
Besifloxacin 0.6%; oph susp; contains benzalkonium chloride.
Bausch & Lomb Inc.
Indications for BESIVANCE:
Susceptible bacterial conjunctivitis.
Adults and Children:
<1yr: not established. ≥1yr: 1 drop in affected eye(s) 3 times daily (4–12hrs apart) for 7 days. Shake bottle once before use.
Not for inj into the eye. Avoid contact lenses during therapy or if symptomatic. Pregnancy. Nursing mothers.
Conjunctival redness, blurred vision, eye pain/pruritus/irritation, headache; superinfection (discontinue and treat).
Clinical Pain Advisor Articles
- Deaths After Nonfatal Opioid Overdose: Causes and Risk Factors
- Treatment for Opioid Use Disorder Associated With Reduced Risk for Opioid-Related Deaths
- Opioid-Free Analgesia Use for Postsurgical Pain Limited
- Clonidine May Not Improve Post-Cesarean Delivery Analgesia
- No Added Value With Liposomal Bupivacaine Following TKA With Peripheral Nerve Block
- Recommendations for Perioperative Pain Management in Patients With Opioid Tolerance
- Vertebroplasty Comparable With Placebo for Acute Vertebral Compression Fractures
- Capsaicin 8% Patch May Be Effective in Neuropathic Pain
- Detox vs Medication-Assisted Treatment for Opioid Use Disorder in Pregnancy: Expert Roundtable
- Prior Authorization Policy May Help Reduce Long-Acting Opioid Use
- Opioid-Related Deaths Represent Significant Public Health Burden
- Addressing Confidentiality Concerns With Electronic Access to Pediatric Medical Records
- Opioid-Related Adverse Events Common After Invasive Procedures
- Diagnosis and Treatment of Migraine in Children Should Consider Atopy
- Led by AG Sessions, DOJ Declines to Defend ACA Against Federal Lawsuit